Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial

AIM: To compare alirocumab, a proprotein convertase subtilisin‐kexin type 9 inhibitor, with usual care (UC) in individuals with type 2 diabetes (T2DM) and mixed dyslipidaemia not optimally managed by maximally tolerated statins in the ODYSSEY DM‐DYSLIPIDEMIA trial (NCT02642159). MATERIALS AND METHOD...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Diabetes Obes Metab
Asıl Yazarlar: Ray, Kausik K., Leiter, Lawrence A., Müller‐Wieland, Dirk, Cariou, Bertrand, Colhoun, Helen M., Henry, Robert R., Tinahones, Francisco J., Bujas‐Bobanovic, Maja, Domenger, Catherine, Letierce, Alexia, Samuel, Rita, Del Prato, Stefano
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Blackwell Publishing Ltd 2018
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5969299/
https://ncbi.nlm.nih.gov/pubmed/29436756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13257
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller